key: cord-0058118-02o0y8zh
authors: Sessa, Maria; Rizzi, Marco; Gerevini, Simonetta
title: Background
date: 2021-03-18
journal: Neuroimaging of Covid-19
DOI: 10.1007/978-3-030-67521-9_2
sha: 050988dda4c9d68c6c8eae98acaeccab326e577b
doc_id: 58118
cord_uid: 02o0y8zh

Human coronaviruses, first characterized in the 1960s, are responsible for a substantial proportion of upper respiratory tract infections in children, with occasional cases of pneumonia in infants and young adults; for a few decades since their first identification, their pathogenicity has been considered to be low; non-respiratory localizations of the disease, including neurological complications, have been described as uncommon events [1]. In the new millennium, new more virulent coronaviruses made their appearance in humans SARS-CoV, causing the Severe Acute Respiratory Syndrome (2002–2004) and MERS-CoV, causing the Middle Eastern Respiratory Syndrome (2012–ongoing); also SARS-CoV and MERS-CoV were mostly associated to respiratory disease, but different organs and body systems could be involved, including the Central Nervous System [2], as recently summarized by Verstrepen et al. [3].

transmembrane protease serine 2 (TMPRSS2) and furin conduce to viral entry [6, 7] ; the downregulation of ACE2 that follows viral binding and entry increases the levels of angiotensin II, with its proinflammatory effects (macrophage activation, increased production and release of IL-6, TNF and other cytokines). On the other hand, ACE2 is mostly expressed by alveolar type II cells, which produce the surfactant, and are the progenitors for AT1 cells (the major constituents of the alveolar cellular lining); SARS-CoV-2, binding to ACE2 and entering AT2 cells, kills AT2 cells, induce a surfactant deficit, and injures the alveolar epithelium. The combined effect of inflammatory activation and alveolar damage may result in a state of hyperinflammation which in a few patients may lead to progressive lung damage and full blown Acute Respiratory Distress Syndrome (ARDS), independently of the persistence of viral replication [8] .

During the SARS epidemic (2002) (2003) (2004) it was demonstrated that SARS-CoV bound to ACE2 receptor [6] . And a number of studies were conducted on the distribution of ACE2 receptors in the human body: it has been shown that ACE2 mRNA is present in almost all organs, but its protein expression is mostly present in lung alveolar cells, enterocytes of the small intestine, arterial and venous endothelial cells and arterial smooth muscle cells: this distribution of ACE2 may be of relevance with regard to the multiorgan manifestations of COVID-19 [9] .

More recent studies on SARS-CoV-2 have demonstrated a high density of ACE2 in the oral and anal mucosae, the heart and the kidney [10] .

Postmortem studies have demonstrated the presence of significant amount of SARS-CoV-2 in lungs, kidneys, liver, heart, bone marrow and brain [11] [12] [13] [14] [15] .

As previously mentioned, following the initial phase of viral replication, a few patients develop an inflammatory response, which in a few most severe cases may be strikingly intense (the socalled cytokine storm) and may lead to vascular hyperpermeability, organ failure and death. Among the immunological features which have been associated with unfavorable outcomes are increased cytokine levels (IL-6, IL-10, and TNFα), lymphopenia (in CD4+ and CD8+ T cells), and decreased IFN-γ expression in CD4+ T cells [16] [17] [18] . On the basis of this evidence, therapeutic strategies have been developed targeting the immune activation: this has included anti-cytokine therapies (such as tocilizumab and sarilumab, targeting the IL-6 receptor, siltuximab, targeting IL-6, anakinra, targeting the IL-1 receptor, eculizumab, an anti-complement agent,) and immunomodulators (such as steroids or colchicine) have been tested, with conflicting results. As of September 30, 2020, conclusive positive results were only available for the use of dexamethasone [19] .

The pathogenesis of hypercoagulability in COVID-19 is still ill-defined. Some experts have postulated that endothelial injury plays a central role in the pathogenesis of acute respiratory distress syndrome and organ failure in patients with severe COVID-19 [20, 21] .

There is evidence of direct invasion of endothelial cells by SARS-CoV-2, potentially leading to cell injury [22, 23] .

On the other end, endothelial injury may be mediated by cytokines, such as interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 10 (IL-10), Tumor Necrosis Factor (TNF-1), and other acute phase reactants. The contribution of complementmediated endothelial injury has also been suggested [24] and experimental COVID-19 therapies targeting these pathogenetic mechanisms have been proposed; there is some preliminary evidence in favor of the use of narsoplimab, a human monoclonal antibody targeting mannan-binding lectinassociated serine protease-2. Narsoplimab, which is approved for the treatment of Hematopoietic Stem Cell Transplant-associated Thrombotic MicroAngiopathy (HSCT-TMA) and atypical Hemolytic Uremic Syndrome (aHUS) down-modulates SARS-CoV-2-induced activation of the lectin pathway and endothelial cell damage, and could reduce the thrombotic risk of COVID-19 patients [25] .

Despite a growing evidence that prothrombotic factors may present high circulating levels in patients with severe COVID-19: this has been observed for D-dimer, fibrinogen, von Willebrand factor, factor VIII, and the well-known frequency and severity of thrombotic events in COVID-19, the best therapeutical approach to anticoagulation remain ill-defined.

While a large amount of data have been collected on hyperinflammation and the "cytokine storm" in the COVID-19 literature, many points remain to be clarified; recently it has been noted that when cytokines levels are measured in COVID-19, they may not result as high as observed in other common conditions, such as sepsis/septic shock, burns and non-COVID-19 related ARDS [26, 27] . This obviously would have great implications for the treatment protocols who aim at downregulating the host inflammatory response in order to prevent organ damage and disease progression: in fact, so far anti-inflammatory treatments have proven of dubious or limited efficacy. In general, the objective of a reduction of the immune response is a tricky one: a well-balanced inflammatory response and coagulation activation are to some degree necessary for pathogen clearance. It should be noted that while a number of biological markers have been investigated as potential tools for the monitoring of inflammation and of the activation of the coagulation pathways (from C-Reactive-Protein to Interleukin 6 to D-dimer), there is still a lack of consensus on the use of these markers in clinical care. It seems reasonable to argue that we need to greatly improve our ability to identify the different phases of the disease (viral invasion and replication, immune response and hyperinflammation, hypercoagulability and thrombotic events), the degree of immune activation, and the different level of organs involvement, so as to be able to make use of finely tuned treatment protocols.

Finally, with regard to the pathogenesis of COVID-19, it has to be noted that the disease is not "switched off" at discharge or whenever the acute phase symptoms subside: the issue of "long-hauling COVID-19" is very much debated; the first available data from follow up studies show that a number of patients still have symptoms a few months after the acute phase, and in some of these patients there is laboratory evidence of persisting immune activation and hypercoagulability; in a series of 743 patients from the Bergamo hospital, at a median of 105 days from symptoms onset, 290 persons (39%) still had raised D-dimer values. This may signal an active disease, with a risk for disease progression and organ damage, including acute severe events, such as major thrombotic episodes; may be that some patients may well deserve some kind of mid-long-term treatment (anti-inflammatory, anticoagulant) in order to reduce the risk of unfavorable outcomes. Much more research is needed in this field.

Growing evidence indicates that the novel coronavirus disease 2019 (COVID- 19) is not limited to the respiratory system and that SARS-CoV-2 has an organotropism beyond the respiratory tract, including the brain. After the first cases of COVID-19 were reported in Wuhan, China, in December 2019, an increasing numbers of case reports and case series report neurological and neuropsychiatric syndromes associated with the disease. However, much is still unknown about their frequency, accurate characteristics, pathophysiology, risk factors, and prognosis.

Up to date, several reports have described the association between respiratory viral infections sustained by different human respiratory virus [syncytial virus (hRSV), the influenza virus (IV), the human metapneumovirus (hMPV), as well as the coronavirus (CoV)] with neurological symptoms. Involvement of both Peripheral Nervous System (PNS) and Central Nervous System CNS has been reported in patients with SARS-and MERS-CoV infections, mostly developing 2-4 weeks after onset of respiratory symptoms. Neuromuscular involvement has been described in three patients with SARS, including polyneuropathy, myopathy and rhabdomyolysis [28] [29] [30] .

Additional cases of peripheral and overlap syndromes have been described in MERS including critical illness neuropathy, Guillain-Barré Syndrome, Bickerstaff's brainstem encephalitis, and toxins (including drugs) or virus-related sensory neuropathy [31, 32] . Ischemic stroke has been described both in SARS [33] and in MERS [34] , as well as hemorrhagic stroke in MERS [31] .

Altered level of consciousness ranging from confusion to coma, associated with MERS-CoV had been described in three patients. Brain magnetic resonance revealed striking changes characterized by widespread, bilateral hyperintense lesions on T2-weighted imaging within the white matter and subcortical areas without gadolinium enhancement, whose characteristics were suggestive of acute disseminated leukoencephalopathy, acute infarction, and encephalitis, respectively [34] .

Experience with Novel SARS-CoV-2 Infection

Prevalence of neurological manifestations in SARS-CoV-2 infection is highly variable ranging from 3.5% up to 84%. However, the precise evaluation of incidence and prevalence is undermined by a series of methodological issues. First of all, "neurological symptoms" are not precisely categorized. In some reports nonspecific complaints based on subjective descriptions, such as dizziness, have been included [35, 36] . In the subsequent publications, nonspecific symptoms likely due to the systemic condition and neurologic symptom fully accounted for by sedation were either excluded or properly classified.

Except for Karadas study all studies were retrospective and data regarding neurologic complications derived from medical records; either mild symptoms or neurological manifestations in highly compromised patients may have been underestimated.

Data were collected either from limited or selected cohort. Helms reports the neurological features of patients with severe ARDS admitted in intensive care units (ICUs) [37] ; Paterson's cases were discussed in the context of multidisciplinary team meeting, thus representing a bias toward more complex and severe cases [38] ; Benussi reports clinical characteristics of patients admitted to a neuro-COVID Unit with neurological disease, excluding therefore all neurological complications occurring in COVID patients hospitalized in other wards and ICUs [39] in the only nation-based study [40] , voluntary-based case notification might have been under-reported because of the clinical demands of the pandemic.

Instrumental evaluations were not systematically performed either to reduce the risk of cross infection [35] or likely due to the well-known difficulties in transferring patients admitted in ICU for instrumental tests [37] .

In the three studies analyzing the main neurological diagnosis/syndromes conducted on all patients with confirmed COVID-19 disease admitted to tertiary care designated COVID-19 hospitals [41] [42] [43] the prevalence was 7.7%, 3.5%, and 7.8% respectively.

Finally, as these studies were hospital based, they do not necessarily reflect the true incidence of neurological manifestations in individuals with SARS-CoV-2 infection in the community. The stay-at-home recommendations/orders and the general fear for the hospital during the COVID-19 pandemic may have prevented patients from presenting to the hospital, in particular older patients and patients with small deficits and mild symptoms.

An open question remains if the neurological manifestations reported in patients with SARS-CoV-2 infection represent coincidental occurrence, common complications during severe infectious disease, or a direct consequence of the viral infection. In the latter case, nervous system damage may either be a consequence of direct viral penetration or secondary to indirect parainfective mechanisms. Several routes of CNS invasion can be used by viral pathogens, among which the hematogenous route or the neurological route through peripheral nerves or olfactory sensory neurons [44] .

Similar to SARS-CoV, COVID-19 virus exploits the angiotensin converting enzyme 2 (ACE2) receptor to gain entry inside the cells. ACE2 receptors are widely distributed on the surface of different cells, among which endothelial cells, neurons, and glial cells. Once in the general circulation SARS-CoV-2 pass into the cerebral circulation and interacts with ACE2 receptors expressed in the capillary endothelium. Subsequent damage of the endothelial lining may be responsible of the viral access to the brain and interaction with ACE2 receptors expressed on neurons and glial cells [45] .

Neuro-invasiveness possibly via the olfactory nerves had been already demonstrated for other coronavirus. Experimental studies using transgenic mice revealed that either SARS-CoV [46] or MERS-COV [47] when given intranasally could enter the brain, possibly via the olfactory nerves, and thereafter rapidly spread to some specific brain areas including thalamus and brainstem. In mice inoculated intranasally with avian influenza virus [48] , viral antigens have been detected in the nucleus of the solitary tract and nucleus ambiguus of the brainstem, The nucleus of the solitary tract receives sensory information from the mechanoreceptors and chemoreceptors in the lung and respiratory tracts [49] ; efferent fibers from the nucleus ambiguus and the nucleus of the solitary tract provide innervation to airway smooth muscle, glands, and blood vessels. These interconnections may provide the neuroanatomic basis of cardiorespiratory dysfunction in COVID-19 patients.

Direct demonstration of viral colonization of CNS in patients infected by coronavirus is scarce. HCoV OC43 has been found in the brain tissue sample obtained from a child with fatal encephalitis [50] . The first demonstration of the entry of SARS-CoV into the CNS was obtained through real-time reverse transcription Polymerase Chain Reaction (RT-PCR) assay targeting the polymerase region (orf1ab polyprotein) of the SARS-CoV genome in the CSF of a SARS patient with status epilepticus [51] . Autoptic studies on the samples from patients with SARS have demonstrated the presence of SARS-CoV particles in the brain [52, 53] . In two out of the three patients described by Arabi with altered level of consciousness, in whom CSF analysis was performed, MERS-CoV RT-PCR was negative [34] .

The detection of SARS-CoV-2 RNA in the CSF by RT-PCR in COVID-19 patients is quite rare. Since the first report in a patient with meningoencephalitis [54] , only few additional cases have been described [55] [56] [57] .

Conclusive pathological demonstrations of the presence of SARS-CoV-2 in the CNS are missing. At postmortem examinations of ten COVID-19 patients, no signs of encephalitis or central nervous system vasculitis were found and RT-PCR for SARS-CoV-2 was negative in all CSF samples [58] .

From an autopsy series of 27 patients quantification of the SARS-CoV-2 viral load by RT-PCR in multiple organs detected SARS-CoV-2 copies at low level per cell also in the brain [13] .

Sampling was obtained from brains of 18 patients who died 0-32 days after the onset of symptoms of COVID-19, all of whom, according to a retrospective chart review by neurologists, presented a state of confusion or decreased arousal from sedation for ventilation. Brain magnetic resonance imaging, electroencephalogram, and cerebrospinal fluid examinations were not performed. Histopathological examination showed only hypoxic changes and did not show encephalitis or other specific brain changes referable to the virus. There was no cytoplasmic viral staining on immunohistochemical analysis. The virus was detected at low levels in six brain sections obtained from five patients [59] .

Electron microscopy studies showed intracytoplasmic vacuoles containing virus-like particles in neural and capillary endothelial cells from frontal lobe brain sections [60] and a spherical particle with size suspicious for a viral particle in the medulla oblongata.

Numerous pathogenic mechanisms contributing to COVID-19 related cerebrovascular syndromes have been proposed. Consistent haemostatic changes in COVID-19 patients, primarily thrombocytopenia and elevated D-dimer levels, indicate some forms of coagulopathy that may predispose to thrombotic events. Nevertheless, it is yet unknown whether these haemostatic changes are a specific effect of SARS-CoV-2 or are a consequence of the cytokine storm [61] . Besides the more common haemostatic alterations, the presence of antiphospholipid antibodies has been reported in some small case series [62] [63] [64] .

In addition, severe endothelial injury associated with intracellular SARS-CoV-2 virus and disrupted endothelial cell membranes as well as widespread vascular thrombosis with microangiopathy and occlusion of alveolar capillaries have been described in the lungs [65] and might also occur in the brain. Finally, SARS-CoV-2 might be responsible of a true vasculitic process.

CVD, in particular acute ischemic stroke (AIS), is emerging as a frequent complication of SARS-CoV-2 infection. Across five studies with a total of 4466 COVID-19 pts [35, 37, [66] [67] [68] . AIS was reported in 54 pts, yielding an overall pooled incidence of 1.2%. Studies were conducted in different countries (France, Netherlands, Italy, China, and the United States) with varying ethnic demographics. Two studies had patient cohorts specifically consisting of patients with severe COVID-19 infection, three included all hospitalized patients with laboratory proven COVID-19 infection [69] . In the Bergamo cohort, CVD represented 38.7% of all neurological manifestations, 70% of which were AIS [43] . The reported median age ranged from 63.4 [69] to 71.2 years [70] . At binary logistic regression analysis comparing AIS COVID positive patients with COVID negative contemporary controls and historical controls, age did not resulted significantly associated with COVID status [68] . Available literature suggests that stroke in COVID positive patients have a higher severity estimated by the National Institute of Health Stroke Scale (NIHSS). In the systematic review and meta-summary of Tan [69] mean NIHHS value was 19. Yagi reported a median value of 19 significantly associated with COVID status at binary logistic regression analysis comparing AIS COVID positive patients with COVID negative contemporary controls and historical controls. In the Global COVID Stroke Registry the median NIHSS was 10 (IQR: [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , and in the 1:1 matched sample of 336 patients with and without COVID-19, the NIHSS was higher in patients with COVID-19 [70] . High NIHSS values are consistent with the frequent observation of large vessel occlusion in a sistematic review [69] , large cohort [68] , registry [70] and in case series [63] .

Available data suggest a poor overall outcome either in terms of in-hospital mortality or residual severe functional deficits assessed by mean of modified Rankin Scale (mRS). Mortality ranged from to 28% in the Global COVID-19 Stroke Registry to 63% in the stroke population admitted to three comprehensive stroke centers in New York. Among [39] .

Besides stroke-related factors, such as large vessel occlusion, other several potential explanations can account for the increased stroke severity and poor outcome, among which the multi-system complications of COVID-19, including acute cardiac injury and cardiac arrhythmias, acute respiratory distress syndrome, pulmonary embolism, shock, cytokine release syndrome, secondary infection [71] .

In addition, the prolonged mechanical ventilation and intensive care unit stay renders patients vulnerable to complications such as hypotension and inadequate cerebral perfusion, superimposed bacterial infection with septic embolization, stress cardiomyopathy, and atrial fibrillation, which represent independent factors for poor prognosis.

Limited data are available concerning outcomes after reperfusion therapies. In the Global COVID-19 Stroke Registry 12 out of 21 (57%) patients treated with intravenous recombinant tissue plasminogen activator (rt-PA) had poor outcome compared to 45% in the non-COVID-19 population registered in the Acute Stroke Registry and Analysis of Lausanne (ASTRAL Registry) between 2003 and 2019. From the same Global COVID-19 Stroke Registry, 11/12 and 8/8 patients treated with thrombolysis plus thrombectomy or with primary endovascular thrombectomy respectively had poor outcome, compared to 3/12 and 3/6 in the ASTRAL Registry [70] . Benussi reported a significant lower number of patients with good outcome in the COVID-19 group, difference that was also confirmed considering only patients who underwent acute phase therapies. Similarly, overall poor outcome is reported in small case series of patients undergoing mechanical thrombectomy [72, 73] .

On the opposite, Rifino reported the case of a 66-year-old woman with basilar artery thrombosis treated with intravenous alteplase followed by a first mechanical thrombectomy with excellent angiographic and clinical outcome, and a second successful thrombectomy, the following day, for the acute occlusion of the M1 segment of right middle cerebral artery.

The STROKOVID network, a joint initiative of ten stroke hub centers in Lombardy region, is collecting comprehensive information on patients hospitalized for acute ischemic stroke in Lombardy during SARS-CoV-2 outbreak and is expected to address clinical and research questions.

Even if less frequent, intracranial hemorrhages have been reported [36, 39, 41] . Out of 755 COVID-19 positive adult patients with available neuroimaging, radiographic evidence of ICH was present in 33. It is of note that, based on review by the study neuroradiologist, 26/33 bleeds were considered to have suffered hemorrhagic conversion of an ischemic infarct [74] .

Single cases of cerebral venous thrombosis have been described, especially in young patients [75] [76] [77] .

Patients presenting with impaired vigilance, confusion and disorientation, psychosis, seizures are commonly described [36, 37, 40, 41, 43] with a very different prevalence values ranging from 9.6% up to 65%. The exact prevalence of these manifestations is limited by the above-mentioned methodological issues, mainly represented by the different cohorts evaluated, and the limited access to diagnostic, which makes very likely that different nosological entities are included in this category.

In the ALBACOVID Registry disorders of consciousness were the most observed neurologic symptoms (19.6%), especially in the severe COVID-19 group and in the advanced stages of COVID-19 disease. These manifestations were statistically associated with older age [78] . In Paterson's series patients were mostly >50 years, neuroimaging was within normal limits, and CSF studies were normal when performed [38] .

By definition, encephalitis is an inflammatory process with diagnostic supportive evidences, which include the presence of a CSF pleocytosis and elevated protein, MRI consistent with inflammation, seizures on electroencephalogram. However, in the majority of the CSF samples obtained from COVID-19 patients with clinical presentation suggestive of encephalitis, signs of inflammation are modest or even absent [37, 38, 78] . Experimental data on transgenic mice expressing the human SARS-CoV receptor, where viral entry in CNS was associated with neuronal injury, but relatively limited inflammation, support real-life observations [46] .

Definitive evidence of viral neuro-invasion would include a positive CSF RT-PCR for SARS-CoV-2, intrathecal synthesis of SARS-CoV-2specific antibodies, or detection of SARS-CoV-2 antigen or RNA in brain tissue.

Cases meeting strict criteria for encephalitis resulting from direct SARS-CoV-2 spreading to the CNS are currently two [54, 79, 80] .

More frequent are the description of cases with inflammatory features in the absence of CNS viral invasion, which raises the possibility that some cases of COVID-19 inflammatory encephalopathies could result from immune-mediated mechanisms.

Two patients were described with nuchal rigidity, altered mental status, mild CSF lymphocytic pleocytosis (17-21 cells/μL 3 ) and elevated CSF protein (46-47 mg/dL), negative RCSF T-PCR for SARS-CoV-2, and normal MRI [81] .

Pilotto et al. describe a 60-year-old man with confusion, irritability, apathy progressing to "akinetic mutism" and nuchal rigidity, with improvement coincident to administration of high dose methylprednisolone. The CSF showed a mild lymphocytic pleocytosis (18 cells/μL 3 ), elevated protein (70 mg/dL), and RT-PCR negative twice for SARS-CoV-2. An EEG showed generalized slowing. The CT and MRI were normal [82] .

Six patients with severe ARDS and depressed consciousness and/or agitation were considered to have "autoimmune meningoencephalitis". CSF cellularity was normal in all patients and protein level was elevated in five (52-131 mg/ dL). In three patients MRI showed cortical hyperintensities with sulcal effacement. Patients were felt to have responded to plasma exchange [83] .

Paterson described one patient with opsoclonus, stimulus sensitive myoclonus and convergence spasm, in whom a diagnosis of autoimmune brainstem encephalitis, despite brain imaging, EEG and CSF were normal, and a second patient with confusion and a single seizure, with MRI abnormalities suggestive of autoimmune or 'limbic' encephalitis in the thalami, medial temporal regions and pons [38] .

Seven cases of encephalitis no further characterized are described in a UK-surveillance study on neurological and neuropsychiatric complications of COVID-19 [40] .

In Paterson's series nine patients were categorized within the spectrum of ADEM. Four patients had hemorrhagic change on imaging and one had necrosis; two patients had myelitis in addition to brain imaging changes. Brain biopsy from one patient, performed at the time of decompressive craniectomy showed evidence of perivenular inflammation supporting aggressive hyper-acute ADEM. A full clinical response was seen in 1 of 12, partial recovery at the time of writing in 10 of 12, and one patient died. Treatments were with corticosteroids in nine, and IVIG in three. Despite the severe imaging findings, the CSF parameters were abnormal in only half. When tested, specific antibodies to NMDAR, MOG, AQP4, LGI1, or GAD were absent in the serum or CSF.

Additional Cases of Acute Demyelinating Encephalomyelitis (ADEM) and Acute Necrotizing Encephalitis (ANE) have been reported. Whenever tested, CSF studies were unremarkable including negative RT-PCR for SARS-CoV-2 [84, 85] .

Twenty-five cases of encephalitis in COVID-19 patients were included in the ENCOVID multicenter study recruited from 13 centers in northern Italy. CSF showed hyper proteinorrachia and/or pleocytosis in 68% of cases whereas SARS-CoV-2 RNA by RT-PCR resulted negative. Based on MRI, cases were classified as ADEM, limbic encephalitis, encephalitis with normal imaging and encephalitis with MRI alterations. ADEM and limbic encephalitis cases showed a delayed onset compared to the other encephalitis and were associated with previous more severe COVID-19 respiratory involvement. Patients with MRI alterations exhibited worse response to treatment and final outcomes compared to other encephalitis [86] .

An increasing number of acute myelitis is accumulating. In all of them, when tested, RT-PCR for SARS-CoV-2 in cerebrospinal fluid (CSF) was negative. Except for the case of one patient, dead for cardiac arrest [87] in all other cases a good response to iv steroid has been reported [88] [89] [90] .

A case of acute necrotizing myelitis has been also described [91] .

An additional case presenting with acute flaccid paralysis of bilateral lower limbs and sphincter incontinence has been described. However, no CSF analysis nor spinal magnetic resonance images (MRI) were performed, making diagnosis of myelitis presumptive [92] .

Rifino reports two cases of myelitis, in whom extensive work-up excluded known causes of myelitis RT-PCR for SARS-CoV2 in CSF was negative. However, CSF IgG antibodies to SARS-CoV2 were present in both patients. Due to their clinical history of fever, the evidence of blood IgG anti-SARS-CoV2, and the lag-time between the onset of COVID-19 symptoms and neurological manifestations, a post-infectious aetiology has been proposed. In only one previous case IgG antibodies to SARS-CoV2 were tested in CSF, and no specific intrathecal synthesis of Anti-SARS-CoV IgG was present [90] .

In two cases, myelitis was associated with acute motor axonal neuropathy (AMAN). In one report, the patient was treated with methylprednisolone 1 g IV for 5 days without improvements. Signs of peripheral neuropathy appeared 3 weeks after her initial onset of symptoms. Spinal fluid analysis and EMG confirmed the diagnosis of AMAN. The patient received five rounds of plasma exchange and started to make some clinical recovery 4-5 weeks after her clinical presentation [93] . In a second case, AMAN was associated with myelitis and anti-GD1b positivity after SARS-CoV-2 infection. The patient underwent plasma exchange followed by one course of intravenous immunoglobulins, partially recovering the strength in the upper limbs [94] .

Antibody-Associated Optic Neuritis and Myelitis has been described with excellent recover after iv steroid [95] .

Loss of smell and taste is the most frequently reported symptoms resulting from involvement of the PNS in patients with COVID-19. A recent meta-analysis has shown that anosmia/hyposmia/dysomia and ageusia/hypogeusia/dysgeusia have an estimated global prevalence of 48% and 41% in patients with COVID-19, respectively. Both symptoms may affect one third of patients. These can manifest in the early stages of viral infection, even in pauci symptomatic patients and can persist over time, after the acute phase of the disease [96] .

After the first reports of Guillain-Barré syndrome [97] [98] [99] numerous additional case reports of GBS and its variants have been published [55, [100] [101] [102] [103] .

Considering the interval between the onset of COVID-19 disease and symptoms of GBS and its variants, both para-infective and post-infective mechanisms have been postulated. An ongoing network among seven cities from northern Italy, in the epicenter of pandemic, is collecting data from patients with GBS diagnosed during the outbreak of SARS-CoV-2 infections.

Neuroinvasion by human respiratory coronaviruses

Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses

Neurological manifestations of COVID-19, SARS and MERS

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

COVID-19: towards understanding of pathogenesis

Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus

Structural basis of receptor recognition by SARS-CoV-2

ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

COVID-19 and multiorgan response

Multiorgan and renal tropism of SARS-CoV-2

Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China

Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study

CoV-2: a storm is raging

COVID-19 cytokine storm: the interplay between inflammation and coagulation

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Dexamethasone in hospitalized patients with covid-19-preliminary report

COVID-19 is, in the end, an endothelial disease

Severe COVID-19 is a microvascular disease

COVID-19: the vasculature unleashed

Endothelial cell infection and endotheliitis in COVID-19

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases

Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab

IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome

Cytokine levels in critically ill patients with COVID-19 and other conditions

Neuromuscular disorders in severe acute respiratory syndrome

Peripheral nerve disease in SARS

Rhabdomyolysis associated with probable SARS

Neurological complications of middle east respiratory syndrome coronavirus: a report of two cases and review of the literature

Neurological complications during treatment of middle east respiratory syndrome

Large artery ischaemic stroke in severe acute respiratory syndrome (SARS)

Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

A prospective clinical study of detailed neurological manifestations in patients with COVID-19

Neurologic features in severe SARS-CoV-2 infection

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings

Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study

Neurological manifestations and COVID-19: experiences from a tertiary care center at the Frontline

New onset neurologic events in people with COVID-19 in 3 regions in China

Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital

Neurologic alterations due to respiratory virus infections

Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Middle east respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4

The vagus nerve is one route of transneural invasion for intranasally inoculated influenza A virus in mice

CNS innervation of vagal preganglionic neurons controlling peripheral airways: a transneuronal labeling study using pseudorabies virus

Human coronavirus OC43 associated with fatal encephalitis

Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome

Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways

Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease

Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid

Brain MRI findings in severe COVID-19: a retrospective observational study

Postmortem examination of patients with COVID-19

Neuropathological features of Covid-19

Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review

Coagulopathy and antiphospholipid antibodies in patients with Covid-19

Characteristics of ischaemic stroke associated with COVID-19

Lupus anticoagulant is frequent in patients with Covid-19

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

SARS-CoV-2 and stroke in a New York healthcare system

COVID-19 and ischemic stroke: a systematic review and metasummary of the literature

Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke

Coronavirus disease 2019 (covid-19): clinical features

Stroke and mechanical thrombectomy in patients with COVID-19: technical observations and patient characteristics

Large-vessel stroke as a presenting feature of Covid-19 in the young

Hemorrhagic stroke and anticoagulation in COVID-19

Cerebral deep venous thrombosis and COVID-19: case report

Venous cerebral thrombosis in COVID-19 patient

Concomitant brain arterial and venous thrombosis in a COVID-19 patient

Neurologic manifestations in hospitalized patients with COVID-19

Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in Downtown Los Angeles

SARS-CoV-2 detected in cerebrospinal fluid by PCR in a case of COVID-19 encephalitis

Du Pasquier R. Two patients with acute meningoencephalitis concomitant with SARS-CoV-2 infection

Steroidresponsive encephalitis in coronavirus disease 2019

Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: case series

COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features

COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia

Clinical presentation and outcomes of SARS-CoV-2 related encephalitis: the ENCOVID multicentre study

Acute flaccid myelitis in COVID-19

Acute myelitis as a neurological complication of Covid-19: a case report and MRI findings

Acute transverse myelitis in COVID-19 infection

Acute transverse myelitis after COVID-19 pneumonia

COVID-19-associated acute necrotizing myelitis

Acute myelitis after SARS-CoV-2 infection: a case report

Acute necrotizing myelitis and acute motor axonal neuropathy in a COVID-19 patient

A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection

Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19

Systematic review and meta-analysis of smell and taste disorders in COVID-19

Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?

Guillain-Barré syndrome related to COVID-19 infection

Guillain-Barré syndrome associated with SARS-CoV-2

COVID-19-associated miller fisher syndrome: MRI findings

Miller Fisher syndrome diagnosis and treatment in a patient with SARS-CoV-2

Miller-Fisher syndrome after SARS-CoV-2 infection

New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases